Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (71-80 of 352) with videos related to

Pageof 36
Sort By:
Journal of Crohn'S & Colitis|August 12, 2025
Impact of Concomitant Corticosteroid Use on Adverse Events in Ulcerative Colitis Clinical TrialsHasan Hamam, Parambir S Dulai, John K Marshall, et al.
Journal of Crohn'S & Colitis|February 23, 2023
Combined Histological and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared with Endoscopic Improvement Alone in Ulcerative Colitis: A Post hoc Analysis of the VARSITY studyEmily C L Wong, Parambir S Dulai, Badar Hasan, et al.
Journal of Crohn'S & Colitis|January 13, 2025
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel diseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Inflammatory Bowel Diseases|June 28, 2022
The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
The American Journal of Gastroenterology|January 18, 2024
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
The American Journal of Gastroenterology|April 18, 2022
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 10, 2015
Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trialsAnthony Lopez, Alexander C Ford, Jean-Frédéric Colombel, et al.
Inflammatory Bowel Diseases|November 24, 2025
Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative ColitisEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Digestive Diseases and Sciences|January 16, 2023
Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical RemissionNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Digestion|October 29, 2003
An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's diseaseClemens Dejaco, Conny Lichtenberger, Wolfgang Miehsler, et al.
Pageof 36

Showing results (71-80 of 352) with videos related to

Sort By:
Pageof 36
Journal of Crohn'S & Colitis|August 12, 2025
Impact of Concomitant Corticosteroid Use on Adverse Events in Ulcerative Colitis Clinical TrialsHasan Hamam, Parambir S Dulai, John K Marshall, et al.
Journal of Crohn'S & Colitis|February 23, 2023
Combined Histological and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared with Endoscopic Improvement Alone in Ulcerative Colitis: A Post hoc Analysis of the VARSITY studyEmily C L Wong, Parambir S Dulai, Badar Hasan, et al.
Journal of Crohn'S & Colitis|January 13, 2025
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel diseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Inflammatory Bowel Diseases|June 28, 2022
The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
The American Journal of Gastroenterology|January 18, 2024
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
The American Journal of Gastroenterology|April 18, 2022
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 10, 2015
Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trialsAnthony Lopez, Alexander C Ford, Jean-Frédéric Colombel, et al.
Inflammatory Bowel Diseases|November 24, 2025
Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative ColitisEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Digestive Diseases and Sciences|January 16, 2023
Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical RemissionNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Digestion|October 29, 2003
An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's diseaseClemens Dejaco, Conny Lichtenberger, Wolfgang Miehsler, et al.
Pageof 36